In this review, the identification of head and neck cancers, apart from those that have BRCA-1 and 2 mutations, which would be sensitive to PARP inhibitors by using different biomarkers, was pointed out as an important issue and discussed in some detail [64]. The gene discussed is BRCA1; the disease is head and neck cancer.